guest ::
| Home > Publications database > Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits. > print |
| Home > Publications database > Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits. > print |
| 001 | 21472 | ||
| 005 | 20210129210800.0 | ||
| 024 | 7 | _ | |2 pmid |a pmid:21919560 |
| 024 | 7 | _ | |2 DOI |a 10.1080/13554794.2011.568502 |
| 024 | 7 | _ | |2 WOS |a WOS:000302400900009 |
| 024 | 7 | _ | |a altmetric:21808179 |2 altmetric |
| 037 | _ | _ | |a PreJuSER-21472 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 084 | _ | _ | |2 WoS |a Clinical Neurology |
| 084 | _ | _ | |2 WoS |a Psychiatry |
| 084 | _ | _ | |2 WoS |a Psychology |
| 100 | 1 | _ | |a Schilbach, L. |b 0 |0 P:(DE-HGF)0 |
| 245 | _ | _ | |a Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits. |
| 260 | _ | _ | |a London [u.a.] |b Psychology Press |c 2012 |
| 300 | _ | _ | |a 152 - 159 |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 440 | _ | 0 | |a NeuroCase |0 26026 |y 2 |v 18 |
| 500 | _ | _ | |a Record converted from VDB: 12.11.2012 |
| 520 | _ | _ | |a Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for Parkinson's disease, but can lead to adverse effects including psychiatric disturbance. Little is known about the risk factors and treatment options for such effects. Here, we describe a patient who reproducibly developed stimulation-induced hypomania when using ventrally located electrodes and responded well to pharmacological intervention while leaving the stimulation parameters unchanged to preserve motor benefits. In spite of clinical remission, [¹⁵O]-positron-emission-tomography (PET) demonstrated activation patterns similar to those reported during mania. This case, therefore, highlights an important treatment option of adverse effects of DBS, but also points toward the need for investigations of its risk factors and their underlying neurobiological mechanisms. |
| 536 | _ | _ | |0 G:(DE-Juel1)FUEK409 |2 G:(DE-HGF) |x 0 |c FUEK409 |a Funktion und Dysfunktion des Nervensystems (FUEK409) |
| 536 | _ | _ | |a 89572 - (Dys-)function and Plasticity (POF2-89572) |0 G:(DE-HGF)POF2-89572 |c POF2-89572 |x 1 |f POF II T |
| 588 | _ | _ | |a Dataset connected to Web of Science, Pubmed |
| 650 | _ | 2 | |2 MeSH |a Antimanic Agents: therapeutic use |
| 650 | _ | 2 | |2 MeSH |a Bipolar Disorder: drug therapy |
| 650 | _ | 2 | |2 MeSH |a Bipolar Disorder: etiology |
| 650 | _ | 2 | |2 MeSH |a Clozapine: therapeutic use |
| 650 | _ | 2 | |2 MeSH |a Deep Brain Stimulation: adverse effects |
| 650 | _ | 2 | |2 MeSH |a Humans |
| 650 | _ | 2 | |2 MeSH |a Male |
| 650 | _ | 2 | |2 MeSH |a Middle Aged |
| 650 | _ | 2 | |2 MeSH |a Parkinson Disease: therapy |
| 650 | _ | 2 | |2 MeSH |a Treatment Outcome |
| 650 | _ | 2 | |2 MeSH |a Valproic Acid: therapeutic use |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Antimanic Agents |
| 650 | _ | 7 | |0 5786-21-0 |2 NLM Chemicals |a Clozapine |
| 650 | _ | 7 | |0 99-66-1 |2 NLM Chemicals |a Valproic Acid |
| 650 | _ | 7 | |a J |2 WoSType |
| 653 | 2 | 0 | |2 Author |a Subthalamic nucleus |
| 653 | 2 | 0 | |2 Author |a Deep brain stimulation |
| 653 | 2 | 0 | |2 Author |a Parkinson's disease |
| 653 | 2 | 0 | |2 Author |a Stimulation-induced hypomania |
| 653 | 2 | 0 | |2 Author |a Pharmacological treatment |
| 653 | 2 | 0 | |2 Author |a Positron-emission-tomography (PET) |
| 700 | 1 | _ | |a Weiss, P.H. |b 1 |u FZJ |0 P:(DE-Juel1)131748 |
| 700 | 1 | _ | |a Kuhn, J. |b 2 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Timmermann, L. |b 3 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Klosterkötter, J. |b 4 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Huff, W. |b 5 |0 P:(DE-HGF)0 |
| 773 | _ | _ | |a 10.1080/13554794.2011.568502 |g Vol. 18, p. 152 - 159 |p 152 - 159 |q 18<152 - 159 |0 PERI:(DE-600)1497469-1 |t Neurocase |v 18 |y 2012 |x 1355-4794 |
| 856 | 7 | _ | |u http://dx.doi.org/10.1080/13554794.2011.568502 |
| 909 | C | O | |o oai:juser.fz-juelich.de:21472 |p VDB |
| 913 | 2 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |2 G:(DE-HGF)POF3-500 |v (Dys-)function and Plasticity |x 0 |
| 913 | 1 | _ | |a DE-HGF |0 G:(DE-HGF)POF2-89572 |v (Dys-)function and Plasticity |x 1 |4 G:(DE-HGF)POF |1 G:(DE-HGF)POF3-890 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-800 |b Programmungebundene Forschung |l ohne Programm |
| 914 | 1 | _ | |y 2012 |
| 915 | _ | _ | |a JCR/ISI refereed |0 StatID:(DE-HGF)0010 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 920 | 1 | _ | |k INM-3 |l Kognitive Neurowissenschaften |g INM |0 I:(DE-Juel1)INM-3-20090406 |x 0 |
| 970 | _ | _ | |a VDB:(DE-Juel1)137462 |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a ConvertedRecord |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|